NASDAQ · Biotechnology · USD

Kiora Pharmaceuticals, Inc. (KPRX) Stock Analysis

Kiora Pharmaceuticals, Inc. (KPRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KPRX

$2.34

+$0.01 (+0.43%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KPRX with… →

KPRX Key Statistics

As of Oct 21, 2026

Trading

Open: $2.35
Previous Close: $2.33
Day's Range: 2.32–2.37
52-Week Range: 1.77–2.91
Volume: 30.13K
Beta: −0.22

Valuation

Market Cap: $10.35M
P/E Ratio: unprofitable
EPS (ttm): −2.46

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$10.84M−401.42%
Shares Outstanding: 4.42M
1-Year Return: −5.26%

Dividend and dates

Avg Volume: 15.88K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KPRX closed at $2.34, −5.26% over 1 year.

Kiora Pharmaceuticals, Inc. (KPRX) has a market capitalization of $10.35M.

In fiscal 2025, KPRX reported revenue of $0.00.

KPRX Stock Return by Calendar Year

Kiora Pharmaceuticals, Inc. (KPRX) 10-year return: what $10,000 became

1 year: $10,000 $9,474; −5.26%
5 years: $10,000 $33; −99.67%
10 years: $10,000 $3; −99.97%

If you had invested $10,000 in Kiora Pharmaceuticals, Inc. (KPRX) 10 years ago, at the close on October 21, 2016, it would have been worth $3 at the close on October 21, 2026: −99.97% in total, −56.10% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+43.66%−94.32%+18.78%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+18.78%
2025	−40.30%
2024	−29.76%
2023	−84.78%
2022	−94.32%
2021	−69.37%
2020	−50.80%
2019	+43.66%
2018	−56.54%
2017	−34.36%
2016 (partial year)	−23.11%

As of October 21, 2026.

KPRX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$10.84M	—
2024	$16.00M	$3.59M	22.5%
2023	$0.00	−$12.51M	—
2022	$0.00	−$13.58M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$9.46M	−$10.84M	—
2024	$16.00M	—	$5.58M	$3.59M	22.5%
2023	$0.00	—	−$8.69M	−$12.51M	—
2022	$0.00	—	−$11.73M	−$13.58M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

The market values Kiora Pharmaceuticals, Inc. (KPRX) at $10.35M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 13 employees.

The 52-week range on file runs from $1.77 to $2.91. KPRX last closed at $2.34 on October 21, 2026. That is +$0.01 (+0.43%) against the previous close. The latest close sits 32.58% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Against the prior fiscal year total of $16.00M, that is a change of −100.00%. The same year closed with a net loss of $10.84M. Trailing earnings per share are −2.46.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −5.26%. Measured over 10 years, that is −56.10% a year compounded. The reported beta is −0.22. Annualized volatility over the trailing 10 years is 113.89%.

Growth & Income

The record shows no dividend for KPRX.

The strongest complete calendar year on file is 2019 at +43.66%; the weakest is 2022 at −94.32%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the total return is +18.78%.

Peer Comparison

Kiora Pharmaceuticals, Inc. (KPRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Kiora Pharmaceuticals, Inc.	KPRX	$10.35M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Kiora Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Visit website →